Drug Trial Radar · NCT06046742
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 10, 2024
Primary completion
Jun 30, 2028
Study completion Dec 20, 2028
Sponsor
- Lead sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
- Solid Tumor
Interventions
M1-c6v1Biological
Intravenous drip administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of intravenous M1-c6v1 in Patients with advanced malignant tumorsTime frame: About 2 years
- Evaluate dose-limiting toxicities (DLTs) and determine the recommended phase 2 dose (RP2D) of single-agent intravenous administration of M1-c6v1.Time frame: About 2 years
- Conduct a dose extension study to evaluate the safety and tolerability of intravenous administration of M1-c6v1 at maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.Time frame: About 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan · Recruiting
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan · Recruiting
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.